29 results about "Imaging agent" patented technology

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of: ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-Porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of: cRGD, dPSMA-617 or KUE, FAP, Bombesin Receptor Binding Vector, or Octreotide Binding Vector, or one or more of the peptides selected from SEQ ID Nos: 1 to 4.

Described herein are 1,2-dioxetane dimers that are useful as chemiluminescent probes, diagnostic agents, and imaging agents. Also described herein are compositions containing such compounds and methods of using the same.

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More particularly, the invention provides a particle comprising a MOF, optionally at least one targeting moiety and at least one short-lived radionuclide; a composition comprising said particle; said particle or composition for use as an imaging agent; said particle or composition for use in a method for the diagnosis of a proliferative disease; said particle or composition for use in a method for the diagnosis of a chronic inflammatory disease; and a kit comprising a particle comprising a MOF, an optional targeting moiety, and a short-lived radionuclide cation.

Provided herein are methods for the surgical removal of lung cancer tissue using CXL, a near-infrared fluorescent imaging agent. This approach involves administering a pharmaceutical composition containing CXL intravenously to a patient, detecting a fluorescence signal emitted from lung cancer tissues, and surgically excising the identified cancerous tissue. Administration doses may range from about 0.001 mg / kg to about 0.10 mg / kg, occurring between up to 4 days and about 1 hour before imaging. The method supports endoscopic imaging and surgeries, including thoracoscopic lung tissue resection, intraoperative visualization, and histopathological evaluation to confirm tissue removal. Exclusion criteria cover hypersensitivity history, renal impairment, and specific laboratory markers exceeding defined limits.

The present invention is based, at least in part, on the discovery that replacing a key bond in a NIR fluorophore with a carbon-carbon bond conjugated to a targeting ligand results in greatly improved stability while retaining ligand and zwitterion properties compared to near infrared fluorophores that do not contain a carbon-carbon bond conjugated to a targeting ligand. In at least one aspect, the present invention provides an imaging agent dye comprising a charge balancing imaging agent conjugated to a targeting vector, wherein the targeting vector is a PSMA binding vector such as dPSMA-617 or KUE, a FAP binding vector, a xenopsin receptor binding vector, or a somatostatin receptor binding vector, and the charge balancing imaging agent is ZW-800-1, ZW-830-1, or ZW-700-1-Forte.

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of a cRGD, a dPSMA-617 or a KUE, a FAP, a bombesin receptor binding vector, or a octreotide binding vector, or one or more of peptides selected from SEQ ID No: 1-4.

A radioactively labeled ligand for a fibroblast activation protein-alpha imaging agent and a preparation method therefor are provided. The radioactively labeled ligand for the fibroblast activation protein-alpha imaging agent has structural formal (I). The compound has a good 68Ga labeling property, a high stability and a good affinity for FAP tumors. The radioactively labeled ligand for 68Ga-labeled FAPi can be used as a tumor positron imaging agent.

The application belongs to the field of fluorescent probes, and relates to a lysosome-targeting fluorescent probe and a preparation method and application thereof. An intermediate is prepared by mixing an aldehyde compound, 5-amino fluorescein and 7-bromoheptanoic acid, and then performing a reaction; the intermediate is mixed with morpholine, and then a reaction is performed, so that the lysosome-targeting fluorescent probe is obtained. The application belongs to the construction of a complex molecular system with flexible and modular Ugi four-component reaction, adopts a one-pot method, and is synthesized by a framework template conjugation method, and the yield of the product is between 60% and 80%. The fluorescent probe prepared in the application can target lysosomes, and can be used as a lysosome-targeting imaging agent for living cancer cells. The fluorescent probe containing ferrocene prepared in the application can target lysosomes, and can be used as a lysosome-targeting imaging agent and a therapeutic agent for living cancer cells. The fluorescent probe containing ferrocene prepared in the application can effectively inhibit the growth of Hela and other cancer cells.

Disclosed are substituted heterocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of formula (I) as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The disclosure further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

This disclosure provides, for example, benzo[c][1,2,5]thiadiazolyl compounds and methods using these compounds for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. This disclosure provides, 11 C, 18 F, or 123 / 125 The invention also provides methods using benzo[c][1,2,5]thiadiazolyl compounds radiolabeled with radioisotopes such as I, as well as radiolabeled compounds for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for diagnosing and / or monitoring the treatment of neurodegenerative disorders.

This application discloses a single-domain antibody targeting GPRC5D and related materials and applications, belonging to the field of biomedical technology. The technical problem this application aims to solve is how to achieve sensitive and efficient detection and / or precise targeted therapy for GPRC5D. To solve this technical problem, this application provides a single-domain antibody with amino acid sequences of CDR1, CDR2, and CDR3 as shown in positions 31-35, 50-66, and 99-105 of SEQ ID NO:1, respectively. This single-domain antibody has a high affinity for the GPRC5D protein and can specifically recognize and target GPRC5D-positive cells. By binding to radionuclides, anticancer agents, or contrast agents, this single-domain antibody can be developed into a targeted imaging agent for multiple myeloma, an immunotherapy drug (vaccine), or a single-domain antibody-drug conjugate, which can be used for early tumor diagnosis, immune monitoring, and targeted therapy.

The present invention relates to variable domain of heavy chain-only (VHH) antibody binding specifically to the transferrin receptor 1 (TfR1) and uses thereof to transport therapeutic agents or imaging agents into cells and over the blood brain barrier.

A nucleic acid aptamer fluorescent probe can be used to prepare medical imaging targeted imaging agents or in vitro diagnostic reagents.

This invention specifically discloses a photoacoustic nanorobot, its preparation method, and its applications, relating to the field of atherosclerotic plaque imaging technology, and particularly to a photoacoustic imaging agent for atherosclerotic plaques. The photoacoustic nanorobot provided by this invention uses the plaque's unique high-lipid environment as a signal "switch," targets unwinding collagen—which is directly related to plaque mechanical stability—as the imaging target, and combines active chemotactic movement capabilities to achieve targeted penetration and heterogeneity analysis, thereby realizing specific enhanced imaging of vulnerable plaques.

The present invention relates to zwitterionic metal chelators and their use as imaging agents, diagnostic agents, chemical processing agents, and therapeutic agents. These zwitterionic metal chelators have desirable properties of maximizing solubility in aqueous environments, minimizing non-specific interactions, and retaining targeting ability, resulting in improved performance in a variety of medical, agricultural, and chemical processes. In vivo and medical applications, the zwitterionic metal chelators improve signal-to-background ratios and therapeutic windows compared to other metal chelators, while retaining high stability.

The application provides a PET imaging agent targeting a CAIX receptor, a PET imaging agent labeling precursor and a preparation method and application thereof, and belongs to the field of radiopharmaceutical labeling, wherein the PET imaging agent precursor has a structure as shown in formula I, formula II or formula III. The PET imaging agent and the PET imaging agent labeling precursor have the advantages of simple preparation method, short preparation time, high radiochemical yield, good in-vivo and in-vitro stability, high specificity, high uptake and the like, and can accurately and stably detect and locate a tumor or an inflammation site. In addition, the PET imaging agent is a Ga-68 labeled targeting CAIX radioactive probe synthesized based on the chemical structure of acetazolamide, the application can realize qualitative diagnosis of CAIX in a tumor, and can provide reliable basis for accurate diagnosis and correct decision in the stages of clinical staging, treatment decision, efficacy monitoring and the like, and finally realizes precise diagnosis and treatment.

There are provided herein, inter alia, complexes, compositions and methods for the delivery of therapeutic, diagnostic and imaging agents, including nucleic acid, into a cell. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into lung cells and lung tissue, both in vitro and in vivo.

The utility model relates to medical equipment field discloses a gastrointestinal radiography imaging agent storage device, including storage jar, the storage jar top is provided with the mixing subassembly, the storage jar top fixedly connected with the feed pipe, the storage jar side wall fixedly connected with the discharge pipe, the feed pipe with the discharge pipe one end all is provided with the connecting assembly, the connecting assembly includes the installation cavity fixedly connected in the discharge pipe surface, the installation cavity inside fixedly connected with the spring, the spring one end fixedly connected with the limit board, the limit board side wall abuts with the connecting seat, the connecting seat inside is equipped with the annular groove, the connecting seat inside is equipped with first sliding slot relatively, in the utility model, through the structural setting of connecting assembly, solved the discharge pipe inside in the prior art easy to produce residual, in with air long time contact can take place metamorphic, in the subsequent discharge and storage jar inside imaging agent contact can interfere with the product's homogeneity and stability problem.

According to at least one aspect of the present disclosure, there is provided an imaging agent comprising a dye compound conjugated to an antigen-specific targeting vehicle, which can be particularly advantageous as its behavior in vivo can contribute to superior optical imaging properties, for example by significantly increasing the solubility of the dye and / or the targeting vehicle, increasing the target-to-background ratio of the imaged tissue, yielding higher resolution imaging, and ultimately providing better identification of malignant tissue for resection and margin assessment, as well as improved visualization, for example during minimally invasive laparoscopic surgery. A method of imaging tumor cells in a subject can comprise: administering an imaging effective amount of an imaging agent according to at least one embodiment of the present application; irradiating a region in the subject where tumor cells are expected to be found with a wavelength absorbed by the imaging agent; and detecting a signal from the imaging agent.

Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

This disclosure provides, for example, benzo[c][1,2,5]thiadiazole compounds and methods for using these compounds, for example, to treat neurodegenerative diseases such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. This disclosure also provides the use of radioactive isotopes, for example... 11 C 18 F or 123 / 125 I. Methods for using radiolabeled benzo[c][1,2,5]thiadiazole compounds and the use of said radiolabeled compounds as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for the diagnosis of neurodegenerative diseases and / or for monitoring the treatment of neurodegenerative diseases.

Described herein are 1,2-dioxetane dimers that are useful as chemiluminescent probes, diagnostic agents, and imaging agents. Also described herein are compositions containing such compounds and methods of using the same.

This invention relates to anti-CD103 antibodies and their use in the diagnosis, prognosis, monitoring, and treatment of diseases. An imaging agent comprising the anti-CD103 antibody and a detectable label is also disclosed, wherein the antibody does not block CD103 binding to E-cadherin or at least partially blocks CD103 binding to E-cadherin. Treatment methods involve administering the anti-CD103 antibody, optionally conjugated to a cytotoxic agent. Diseases that need to be treated include, for example, hairy cell leukemia, HCLv, intestinal and extraintestinal lymphoma, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Cezari syndrome (SS), Alzheimer's disease, Parkinson's disease, or multiple sclerosis.

According to at least one aspect of this disclosure, an imaging agent is provided comprising a dye compound conjugated to an antigen-specific targeting carrier. This imaging agent can be particularly advantageous because its behavior in vivo can contribute to superior optical imaging properties, such as producing higher resolution imaging by significantly increasing the target-to-background ratio of the imaged tissue, and ultimately providing better identification of malignant tissue for resection and margin assessment, as well as improved visualization, for example, during minimally invasive laparoscopic surgery. A method for imaging tumor cells in a subject may include: administering an imaging-effective amount of the imaging agent according to at least one embodiment of the invention; irradiating an area of ​​the subject where tumor cells are expected to be found with a wavelength absorbed by the imaging agent 2 to 4 hours after administration of the imaging agent; and detecting a signal from the imaging agent to image the tumor cells, wherein the target-to-background ratio is about 2.75 to about 15 2 to 4 hours after administration.

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

The application relates to the technical field of biomedical polymer imaging materials, and discloses a thermoplastic polyurethane imaging composite material as well as a preparation method and application thereof.The raw material components of the thermoplastic polyurethane imaging composite material include thermoplastic polyurethane, modified imaging agents and additives; wherein the modified imaging agents are obtained by the reaction of a modifier and an imaging agent; the modifier includes a reactive silane coupling agent and a flexible high-molecular-chain compound, the flexible high-molecular-chain compound contains hydroxyl groups or carboxyl groups on a molecular chain, the hydroxyl groups or the carboxyl groups can chemically react with organic functional groups in a molecular structure of the reactive silane coupling agent or form hydrogen bonds, and the number-average molecular weight of the flexible high-molecular-chain compound is 300-3000.The preparation method is clear in steps and controllable in conditions, and the prepared thermoplastic polyurethane imaging composite material has excellent X-ray imaging properties, a high mechanical property retention rate and good processing fluidity.

This disclosure relates to fibroin-specific and collagen-specific imaging agents comprising metal oxide nanoparticles.